Sanofi-Aventis Merger Clears Hurdle: Pfizer To Buy Aventis' Camptosar Rights For $620 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis sells irinotecan primarily in Europe, Asia and Africa, and recorded sales of $320 mil. in 2003. Camptosar directly competes with Sanofi's Eloxatin in the colorectal cancer market.
You may also be interested in...
Aventis’ Estorra Rights Acquired By Private Equity Firm For $115 Mil.
The company is divesting its rights in the insomnia drug as part of a Federal Trade Commission consent agreement clearing the Sanofi merger. Paul Royalty Fund II, an affiliate of Paul Capital Partners, will make fixed and milestone payments.
Aventis’ Estorra Rights Acquired By Private Equity Firm For $115 Mil.
The company is divesting its rights in the insomnia drug as part of a Federal Trade Commission consent agreement clearing the Sanofi merger. Paul Royalty Fund II, an affiliate of Paul Capital Partners, will make fixed and milestone payments.
Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger
Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.